Indian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while generics may be exempt, Sun Pharma’s specialty and innovative products, manufactured in countries like South Korea and the EU, could face levies up to 15%. The US administration is reportedly preparing these tariffs, with an announcement possibly today.
